The University of Colorado Comprehensive Cancer Center (UCCC) is the only NCl-designated Cancer Center in Colorado serving a primary catchment area of Colorado and Wyoming with a population of about 5.5 million. The mission of the UCCC is to discover, develop, and deliver breakthroughs in the diagnosis, treatment, and prevention of cancer with the underlying theme of personalized care woven throughout the enterprise. Structured as a matrix center within the Univ. of Colorado School of Medicine, the UCCC is an NCI recognized consortium encompassing Univ. of Colorado Boulder, Colorado State University, National Jewish Health, Univ. of Colorado Hospital, the Children's Hospital, Denver Health System, Kaiser Permanente of Colorado and the Denver Veterans Administration Medical Center. The consortium institutions have made commitments to cancer medicine of approximately $101 million since 2005. There are 248 full members (nearly all NIH funded cancer researchers in the state of Colorado) who participate in six research programs including: Cancer Cell Biology;Molecular Oncology;Developmental Therapeutics;Hormone-Related Malignancies;Lung, Head &Neck Cancer, and Cancer Prevention and Control. During the past five years, peer-reviewed cancer-related funding reached $102 million and 3,181 publications (35% collaborative) were produced. Our innovation in research is exemplified by our members'lead roles in a lung cancer SPORE, LIVESTRONG Center of Excellence, biomarker development (ALK rearrangement, EGFR) for individualized therapy by our Pathology Shared Resource and development of a top Animal Cancer Center. Annual accrual to therapeutic trials increased from 595 to 1,044 which represent 27% of newly diagnosed patients. Research is supported by 13 Shared Resources located across the consortium and accessible to all UCCC members. These resources leverage NIH investments in our Colorado Clinical and Translational Science Institute (CCTSI) to provide cost efficiencies by avoiding duplication and enhancing critical mass. Development activities focused on strategic recruitments and pilot and seed grant programs have led to a return on investment of $11 million in direct cancer research grant funding. During the next five years, our Strategic Plan includes development of programs in Metastasis and Tumor Microenvironment, Cancer Stem Cells, Survivorship and Health Disparities and a Human Research Imaging Shared Resource which will cross species and enhance our drug development pipeline and personalized therapy clinical trials. Additional clinical and research facilities in construction, will allow us to mainain our upward research and clinical growth trajectory.

Public Health Relevance

The NCl-designated Cancer Centers are the centerpiece of the national effort to reduce morbidity and mortality from cancer. As the only NCl-designated Cancer Center in the State of Colorado, the UCCC innovates in the development of more effective approaches to prevention, diagnosis, and therapy of cancer and the deployment of such therapies throughout the state. This application requests renewal of the UCCC's NCl-designated status so we may continue to fight cancer for our community, region, and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-25
Application #
8523796
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-08-06
Project End
2017-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$3,430,389
Indirect Cost
$1,129,808
Name
University of Colorado Denver
Department
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Maccini, Michael A; Westfall, Nicholas J; Van Bokhoven, Adrie et al. (2018) The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer. Prostate 78:506-511
Ye, Haobin; Adane, Biniam; Khan, Nabilah et al. (2018) Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell 34:659-673.e6
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464
Elder, Alan M; Tamburini, Beth A J; Crump, Lyndsey S et al. (2018) Semaphorin 7A Promotes Macrophage-Mediated Lymphatic Remodeling during Postpartum Mammary Gland Involution and in Breast Cancer. Cancer Res 78:6473-6485
Yue, Zongliang; Zheng, Qi; Neylon, Michael T et al. (2018) PAGER 2.0: an update to the pathway, annotated-list and gene-signature electronic repository for Human Network Biology. Nucleic Acids Res 46:D668-D676
Smith, Weston J; Tran, Huy; Griffin, James I et al. (2018) Lipophilic indocarbocyanine conjugates for efficient incorporation of enzymes, antibodies and small molecules into biological membranes. Biomaterials 161:57-68
Morgan, Michael J; Fitzwalter, Brent E; Owens, Charles R et al. (2018) Metastatic cells are preferentially vulnerable to lysosomal inhibition. Proc Natl Acad Sci U S A 115:E8479-E8488
Hartwick, Erik W; Costantino, David A; MacFadden, Andrea et al. (2018) Ribosome-induced RNA conformational changes in a viral 3'-UTR sense and regulate translation levels. Nat Commun 9:5074
Genova, Carlo; Socinski, Mark A; Hozak, Rebecca R et al. (2018) EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol 13:228-236
Greer, Robert O; Eskendri, Jeffrey; Freedman, Paul et al. (2018) Assessment of biologically aggressive, recurrent glandular odontogenic cysts for mastermind-like 2 (MAML2) rearrangements: histopathologic and fluorescent in situ hybridization (FISH) findings in 11 cases. J Oral Pathol Med 47:192-197

Showing the most recent 10 out of 1634 publications